Variability in Intravenous Immunoglobulin G Regimens for Autoimmune Neuromuscular Disorders

References

• . Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004;24(1):17–20
   PubMed Web of Science ®Google Scholar
• . Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst. 2010;15(1):1–9
   Web of Science ®Google Scholar
• . Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–1356
   PubMed Web of Science ®Google Scholar
• . Hughes RA, Donofrio P, Bril V, . Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144
   PubMed Web of Science ®Google Scholar
• . Nobile-Orazio E, Cocito D, Jann S, . Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;U(6):493–502
   Google Scholar
• . Eftimov F, Winer JB, Vermeulen M, de Haan R van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2009;1:CD001797
   PubMed Web of Science ®Google Scholar
• . Abstracts of the 2012 PNS/Inflammatory Neuropathy Consortium Meeting June 24–27, 2012 Rotterdam, The Netherlands. J Peripher Nerv Syst. 2012;17(2):229–282
   Google Scholar
• . Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490
   PubMed Web of Science ®Google Scholar
• . Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–368
   PubMed Web of Science ®Google Scholar
• . Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008;1:CD002277
   Google Scholar
• . Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–841
   PubMed Web of Science ®Google Scholar
• . Gajdos P, Tranchant C, Clair B, . Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689–1693
   PubMedGoogle Scholar
• . Elovaara I, Apostolski S, van Doom P, . EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893–908
   PubMedGoogle Scholar
• . Sewell C, ed. First National Immunoglobulin Database Report (2008–2009). London, UK: Dept of Health, National Health Service; 2010
   Google Scholar
• . Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2006;11(1):1–8
   PubMedGoogle Scholar
• . Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16(5):631–638
   PubMed Web of Science ®Google Scholar
• . Imbach P. 30 years of immunomodulation by intravenous immunoglobulin. Immunotherapy. 2012;4(7):651–654
   PubMed Web of Science ®Google Scholar
• . Pro van D, Stasi R, Newland AC, . International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186
   PubMedGoogle Scholar
• . Berger M; Flebogamma® 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma®. J Clin Immunol. 2007;27(6):628–633
   PubMed Web of Science ®Google Scholar
• . Björkander J, Nikoskelainen J, Leibl H, . Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90(4):286–293
   PubMed Web of Science ®Google Scholar
• . Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2011;68(7):862–869
   PubMedGoogle Scholar
• . Pollard JD, Armati PJ. CIDP—the relevance of recent advances in Schwann cell/axonal neurobiology. J Peripher Nerv Syst. 2011;16(1):15–23
   PubMedGoogle Scholar
• . Dacci P, Riva N, Scarlato M, . Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci. 2010;31(6):829–831
   PubMed Web of Science ®Google Scholar
• . Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. Immune Deficiency Foundation, Towson, MD, USA [online]. 2003. http://primaryimmune.org/about-primary-immunodeficiency-diseases/idf-publications?aid=1266&pid=275&sa=1. Accessed July 4, 2012
   Google Scholar
• . Bexon M, Rojavin M, Jolies S, Ellis S, Sawyer J. The construction of a pharmacokinetic model to describe intravenous and subcutaneous supplementation of IgG in patients with primary immunodeficiency (PID). J Allergy Clin Immunol. 2011;127(2):AB16
   Google Scholar
• . Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532–538
   PubMed Web of Science ®Google Scholar
• . Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133–141
   PubMed Web of Science ®Google Scholar
• . Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122(1):210–212
   PubMed Web of Science ®Google Scholar
• . Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–1360
   PubMed Web of Science ®Google Scholar
• . Gamunex-C [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc; 2010
   Google Scholar
• . Gammagard Liquid [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2012
   Google Scholar
• . Rajabally Y, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic idiopathic demyelinating polyneuropathy. J Peripher Nerv Syst. 2006;11(4):325–329
   PubMed Web of Science ®Google Scholar
• . Kuitwaard K, de Gelder J, Tio-Gillen AP, . Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol. 2009;66(5):597–603
   PubMed Web of Science ®Google Scholar
• . Van Doom PA, Kuitwaard K, Jacobs BC. Serum IgG levels as bio-markers for optimizing IVIG therapy in CIDP. J Peripher Nerv Syst. 2011;16:38–40
   PubMedGoogle Scholar